A deeper understanding of GDF15’s role in atherosclerosis and vascular dysfunction could ultimately inform the development of targeted treatments, enhancing our capacity to understand and address the overlapping pathophysiology of PAD, CAD, and CVD to improve cardiovascular outcomes. This evidence concerns the gene GDF15 and peripheral arterial disease.